GlassScriptPhysician profile
Manju B Sam
NPI 1265067466
$371.52
in general payments reported to CMS, 2019-2025
11 companies · $88.70 in 2025
The $88.70 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $90.35 · 2023: $21.29 · 2024: $30.34 · 2025: $88.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $140.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $80.82 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $58.45 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.89 | 2022 | |
| Novo Nordisk INC | $41.29 | 2023-2025 | |
| Corcept Therapeutics | $29.91 | 2025 | Korlym |
| Amarin Pharma, INC. | $20.38 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $20.06 | 2025 | Breztri |
| Lilly USA, LLC | $18.73 | 2025 | Zepbound |
| Novartis Pharmaceuticals Corporation | $18.65 | 2022 | |
| Inspire Medical Systems, INC. | $15.80 | 2024 | Inspire |
| Idorsia Pharmaceuticals US INC | $14.54 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manju Sam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.